Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.

Rheumatology international - 1 Jun 2013

Jančić Ivan, Arsenović-Ranin Nevena, Sefik-Bukilica Mirjana, Zivojinović Sladjana, Damjanov Nemanja, Spasovski Vesna, Srzentić Sanja, Stanković Biljana, Pavlović Sonja

Abstract excerpt

To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Etanercept

Share to Immunoglobulin G

Share to Interleukin-6

Share to Promoter Regions, Genetic

Share to Receptors, Tumor Necrosis Factor

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 23233117
DOI: 10.1007/s00296-012-2586-y

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.PMID 23233117Read ↗

Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.Semantic proximity Read ↗

Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.Semantic proximity Read ↗

Clinical significance of serum interleukin-6 and −174 G/C promoter polymorphism in Rheumatoid arthritis patientsSemantic proximity Read ↗

IL-6 promoter polymorphism in patients with rheumatoid arthritis.Semantic proximity Read ↗

The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis.Semantic proximity Read ↗

Relationship between polymorphisms in -572G/C interleukin 6 promoter gene polymorphisms (rs1800796) and risk of rheumatoid arthritis: A meta-analysis.Semantic proximity Read ↗

[The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone].Semantic proximity Read ↗

Circulating interleukin-6 and rheumatoid arthritis: A Mendelian randomization meta-analysis.Semantic proximity Read ↗

The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.Semantic proximity Read ↗

The -174G/C and -572G/C interleukin 6 promoter gene polymorphisms in mexican patients with rheumatoid arthritis: a case-control study.Semantic proximity Read ↗

Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis.Semantic proximity Read ↗

Interleukin-6-174G > C (rs1800795) polymorphism distribution and its association with rheumatoid arthritis: A case-control study and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.